secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-08-25T20:04:39+00:00
Accession:  0001636282-26-000105
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre SPY072 RA sub-study shows significant efficacy vs placebo but misses bar for RA monotherapy
--------------------------------------------------------------------------------

- SPY072 Low Dose ΔDAS28-CRP -1.9 (p<0.05) vs placebo -1.3 at Week 12; High Dose ACR20 63% (nominal p<0.05) vs placebo 43%.
- Low Dose ACR50 38% (nominal p<0.05) vs placebo 19%; ACR70 4% vs 2%.
- Adverse events 27% active vs 36% placebo; one serious TEAE per arm, none drug-related; one death in placebo arm.
- Did not meet internal bar to prioritize SPY072 as monotherapy in RA; supports TL1A combo potential.
- PsA/axSpA topline on track Q4 2026; SPY072 + IL-17A/F HS readout late 2027/early 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/0001636282-26-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/syre-20260825.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer